English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduScientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies—one targeting epidermal growth factor receptor (EGFR), the other programmed cell death 1 (PD-1). This dual treatment aims to supercharge the immune system, showing early signs of improving survival and response rates. For patients with no other treatment options, this breakthrough offers a glimmer of hope, potentially changing the trajectory of their fight against cancer.
Tag: Sarcoma
Unlocking the potential of patient-derived organoids for personalized sarcoma treatment
UCLA investigators have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.
MD Anderson Research Highlights for July 11, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, announces that the first U.S. patient has been dosed in the Company’s Phase 3 study to treat metastatic sarcoma (NCT06263231).
Launch of a pioneering translational research programme in Europe
– The TRIP initiative establishes three new joint laboratories that bring together fundamental biomedical research and clinical research with the aim of accelerating the delivery of results to patients.
– TRIP will focus on emerging fields such as immuno-oncology, inflammation, and cellular senescence.
Cleveland Clinic Researchers Uncover How Virus Causes Cancer, Point to Potential Treatment
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi’s sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease.
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
MD Anderson and Replay announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
Tumor microbiome linked to immunotherapy success in sarcoma patients
A new UC Davis study reveals the interaction between tumor microbiome and the immune system may be the secret to improving outcomes for sarcoma patients.
Stopping a rare childhood cancer in its tracks
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a new drug target for Ewing sarcoma, a rare kind of cancer usually diagnosed in children and young adults. Their experiments show that the cells causing this cancer can essentially be reprogrammed with the flick of a genetic switch.
U-M to lead multi-site $12M grant to study rare type of sarcoma
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative SPORE grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle.
Advertencia del experto: Terapia con haz de protones para cáncer de hueso salva al tejido circundante
Julio es el mes para concienciar sobre el sarcoma y llamar la atención sobre aquel grupo de cánceres que empiezan en los huesos o en los tejidos blandos del cuerpo. Hay más de 70 tipos de sarcoma, entre ellos, el cáncer de hueso.
Proton beam therapy for bone cancer spares surrounding tissue
July is Sarcoma Awareness Month, bringing attention to a group of cancers that begin in the bones or soft tissues of the body. There are more than 70 types of sarcoma, including bone cancer. Treatments for bone cancer include surgery, chemotherapy, radiation, or proton beam therapy that targets the cancer.
Answers from an Expert: Sarcoma, the Forgotten Cancer
Adam C. Berger, MD, FACS, chief of Melanoma and Soft Tissue Surgical Oncology and associate director for Shared Resources at Rutgers Cancer Institute of New Jersey addresses common questions about sarcoma during sarcoma awareness month.
Experts stress importance of monitoring for post-treatment opioid use in young sarcoma patients
New analysis finds more than half of U.S. adolescents and young adults with sarcoma—a type of cancer in the bones or soft tissues—are often prescribed opioids to treat their pain.
Discovery of cell protein that keeps Kaposi’s sarcoma herpesvirus dormant
A study led by UC Davis Cancer Center identified a binding protein in cancer cell’s nucleus, known as CHD4, as a critical agent keeping Kaposi’s sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body’s immune system. CHD4 is linked to cancer cell growth in many types of cancers.
MD Anderson Research Highlights: SITC 2021 Special Edition
This special edition of MD Anderson’s Research Highlights features presentations at the Society for Immunotherapy of Caner 36th Annual Meeting.
Return to Care Saves Young Woman with Only 5% Chance of Survival
Doctors from Hackensack University Medical Center’s John Theurer Cancer Center Perform 14-Hour Life Saving Surgery When waking up one morning in April 2020, 23 year-old Zulema Rubio, a recent college grad and legal assistant, experienced swollenness in her face. She…
Shedding light on the Forgotten Cancer
Rutgers Cancer Institute expert sheds light on sarcoma for rare disease day.
Immunotherapy Combo Halts Rare, Stage 4 Sarcoma in Teen
The patient, whose tumor responded within two weeks after receiving the combination, resumed normal activity and was in a complete remission at the time of the report.
Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.
Sarcoma Awareness Month: Orthopaedic oncologists available to comment on the rarity of sarcoma and the work that’s being done to better treatment options for patients
July is Sarcoma Awareness Month. Few people can tell you that sarcoma is a rare cancer of the soft tissue and bone with over 70 subtypes. And even advocacy groups call it “a forgotten cancer.” But for the tens of…